• Ceftazidime in Gram-Negative Resistance Research

  2026-09-04

  Ceftazidime combines strong activity against Pseudomonas aeruginosa with a practical phenotype layer for resistance studies. This workflow pairs susceptibility testing with plasmid localization, gene detection, conjugation, and strain typing to distinguish antibacterial activity from carbapenemase-driven dissemination.

• 3-Aminobenzamide: A PARP Biology Decision Guide

  2026-09-04

  3-Aminobenzamide (PARP-IN-1) is examined here as a mechanistic tool for separating PARP-dependent stress phenotypes from isoform-specific effects. This guide connects oxidative injury, vascular and renal models, and coronavirus macrodomain biology while defining practical controls and interpretation limits.

• Gepotidacin for Uncomplicated Urogenital Gonorrhea

  2026-09-03

  This phase 2 randomized study evaluated whether a single oral dose of the novel bacterial type II topoisomerase inhibitor gepotidacin could eradicate uncomplicated urogenital Neisseria gonorrhoeae infections. Both tested doses produced at least 95% microbiological eradication in the evaluable population, while treatment failures were associated with a common mutation and the highest observed gepotidacin MIC.

• Carbapenemase Gene Transmission in CREC, 2022–2024

  2026-09-03

  Chen et al. mapped carbapenemase-encoding genes, their genomic locations, transferability, and strain relatedness among carbapenem-resistant Enterobacter cloacae collected from eight teaching hospitals in Guangdong. The study shows that blaNDM-1 was frequently plasmid associated, readily transferable in laboratory conjugation, and linked to broader multidrug resistance, highlighting the importance of combining molecular surveillance with epidemiological typing.

• Sisomicin Activity Against Clinical Isolates

  2026-09-02

  The reference study evaluated sisomicin against 565 clinical isolates and positioned it against gentamicin, tobramycin, amikacin, butirosin, and kanamycin using standardized broth-dilution testing. Its main contribution was a broad comparative susceptibility profile showing strong activity against most tested gram-negative bacilli, while also identifying cross-resistance patterns and the relative vulnerability of Serratia marcescens.

• ω-Agatoxin IVA TFA: Assay Design Guide

  2026-09-02

  ω-Agatoxin IVA TFA is a precision Cav2.1 probe for separating calcium-current inhibition from downstream changes in synaptic function. This guide translates its subtype selectivity, cardiac vagal neuron evidence, and epilepsy-model data into practical assay decisions.

• Difloxacin HCl Research Workflows

  2026-09-01

  Difloxacin HCl supports two distinct research workflows: standardized antimicrobial susceptibility testing and exploratory multidrug resistance reversal in neuroblastoma models. This guide connects practical formulation, assay design, controls, and troubleshooting with a mechanistic framework for interpreting drug-response experiments.

• Methicillin Sodium Salt: Assay Design for MSSA

  2026-09-01

  Learn how Methicillin sodium salt can support rigorous MSSA susceptibility, resistance, and gram-positive infection model research. This guide translates clinical trial endpoint design into practical assay decisions without confusing in vitro potency with patient-level efficacy.

• Tetracycline Hydrochloride: Bench Workflow Guide

  2026-08-31

  Build more reliable antimicrobial and microbiome experiments with Tetracycline Hydrochloride, from concentration-range finding to orthogonal confirmation of bacteriostasis. The workflow also shows how recent ROS-driven cancer research can sharpen assay controls without conflating bacterial translation inhibition with platinum nanotherapeutic mechanisms.

• Temafloxacin: From Mechanism to Translational Strategy

  2026-08-31

  Temafloxacin offers a useful translational framework for connecting fluoroquinolone target biology, pathogen-specific susceptibility, intracellular assay design, and historical pharmacokinetic evidence. This article outlines how researchers can move beyond product-page spectrum claims toward exposure-aware, mechanism-informed antibacterial workflows.

• Fenofibrate Workflows for PPARα Research

  2026-08-30

  Fenofibrate is a practical PPARα agonist for connecting lipid metabolism with liver growth and YAP pathway biology. This workflow-oriented guide covers solvent handling, time-course assays, age-aware study design, cancer models, and troubleshooting for reproducible results.

• Faropenem Sodium, AMR, and Rational Use

  2026-08-29

  The reference article frames oral faropenem as both a useful broad-spectrum penem antibiotic and a potential antimicrobial-stewardship problem. Its central contribution is linking oral convenience, expanding consumption, uncertain susceptibility interpretation, and reported cross-resistance with carbapenems to the need for laboratory-guided use.

• Calpain Inhibitor I, ALLN: Practical Guide

  2026-08-28

  Calpain Inhibitor I, ALLN (A2602) is a research reagent for probing calpain I/II and cathepsin B/L activity in apoptosis, inflammation, and ischemia-reperfusion workflows. It helps test whether cysteine-protease activity contributes to an observed phenotype, but it should be used as a mechanistic perturbation in validated laboratory models—not as a diagnostic or therapeutic product.

• Sodium Dicloxacillin Monohydrate: PK/PD Assay Logic

  2026-08-28

  Sodium dicloxacillin monohydrate can serve as more than an MSSA antibiotic control: it enables compartment-aware interpretation of exposure, intracellular activity, and time-dependent pharmacodynamics. This guide translates published dicloxacillin findings into stronger assay-design decisions.

• Natural Compounds Against SARS-CoV-2: Docking Evidence

  2026-08-27

  Eskandari’s 2022 study combined virtual screening, molecular docking, and molecular dynamics to evaluate vitamin-derived compounds against both the SARS-CoV-2 main protease and the spike-protein receptor-binding domain. The results nominate overlapping and target-specific compounds, while also illustrating how computational binding predictions can guide—but not replace—biochemical and cellular validation in antiviral therapeutics research.

7976 records 1/532 page Next 12345 下5页 Last page